Search

Guardant Health, Inc., a precision oncology company, has reported its financial results for the fourth quarter and full year of 2023. In the fourth quarter, the company saw a 22% increase in revenue compared to the same period in 2022, with reported tests to clinical and biopharmaceutical customers increasing by 29% and 16% respectively. For the full year of 2023, revenue increased by 25% compared to 2022, with reported tests to clinical and biopharmaceutical customers increasing by 39% and 15% respectively. The company also improved its operating expenses and free cash flow compared to the previous year and ended the year with $1.2 billion in cash, cash equivalents, and marketable debt securities. Additionally, Guardant Health achieved improved average selling prices with its Guardant360 LDT CMS reimbursement and published a paper demonstrating improved adherence with blood-based colorectal cancer screening. The company also collaborated with the US Oncology Network and community oncology practices to increase the use of biomarker testing for identifying patients who would benefit from therapies. Terilyn Juarez Monroe was appointed as the chief people officer. [Extracted from the article]

A patent has been issued for nanolignocellulose compositions and the processes to produce them. Nanolignocellulose is a nanostructured material derived from biomass, primarily cellulose, hemicellulose, and lignin. It has various applications in industries such as pharmaceuticals, food packaging, textiles, and construction materials. The patent describes a process for producing nanolignocellulose with high hydrophobicity and improved properties, such as increased strength and enhanced paper quality. The nanolignocellulose composition consists of cellulose nanofibrils, cellulose microfibrils, lignin, and hemicelluloses. The patent was filed by inventors from Atlanta, Georgia, and the assignee is GranBio Intellectual Property Holdings LLC based in Thomaston, Georgia. [Extracted from the article]

GSK Consumer Healthcare SARL has been issued a patent for a child-resistant sachet design. The sachet consists of two layers of flexible material joined together to create a cavity, with an outlet tunnel that allows for the dispensing of solid tablets. The outlet tunnel is designed with sequential sections at a non-180° angle to optimize child resistance. The patent was filed in 2016 and published in 2023. This invention aims to address the problem of children easily accessing tablets from sachets while still allowing for easy dispensing for elderly users. [Extracted from the article]

A patent has been issued for oleophilic and hydrophobic nanocellulose materials. Nanocellulose is a nanostructured material derived from biomass that has various applications, such as in polymer reinforcement, biodegradable food packaging, and pharmaceuticals. However, its use has been limited due to moisture sensitivity, incompatibility with certain polymers, and high energy consumption in production. The patent describes a process for producing nanocellulose with improved properties, including increased hydrophobicity and the ability to selectively absorb oil. The invention involves coating cellulose nanofibrils and/or cellulose nanocrystals with lignin to achieve these desired characteristics. The nanocellulose material can be in the form of a coating, layer, foam, aerogel, sponge, or lace, and can be applied to various scaffold materials. The patent also discusses the potential use of the material in oil spill clean-up. The inventors highlight the need for improved processes and materials in the production of nanocellulose. The patent was assigned to GranBio Intellectual Property Holdings LLC. [Extracted from the article]

Baxter International Inc. has been granted a patent for containers with selective dissolved gas content, specifically designed for parenteral nutrition products. The patent focuses on maintaining the stability and potency of oxygen-sensitive compounds by controlling the presence of gases, such as oxygen, in the containers. The containers are made of film materials with high gas-barrier properties and are filled with a selective dissolved gas based on the compound's requirements. The patent also discusses the importance of reducing headspace and the challenges associated with stability. Overall, the patent addresses the technical aspects of container design and gas control in the context of pharmaceutical solutions. [Extracted from the article]

Taro Pharmaceuticals U.S.A., Inc. has introduced a new diaper rash cream spray called bebe Bottoms. Unlike traditional creams, this spray allows for easy, one-handed application without the need for rubbing. The spray is formulated with 10% zinc oxide, organic chamomile, and calendula to create a protective barrier that soothes and heals diaper rash while allowing the skin to breathe. It is gentle enough to be used at every diaper change to prevent future irritation. The spray is available for purchase on Amazon and will be expanding to other retailers soon. [Extracted from the article]

A patent has been issued for a smart self-activating wearable device that automatically injects medicines. The device is designed to treat acute medical conditions that require immediate treatment, such as drug overdose or anaphylactic shock. It overcomes the limitations of current automatic drug injection systems by being wearable, unobtrusive, and requiring no human intervention. The device includes an enclosure, an injection cylinder, an injection piston, hypodermic needles, and a valve member to control the flow of the injected fluid. The patent was filed by Innovative Health Strategies LLC and published online on March 5, 2024. [Extracted from the article]

A method of identifying a C. difficile infection in a subject, comprising: (a) isolating the fecal sample from the subject; and (b) detecting C. difficile in the fecal sample according to the method of claim 1. Keywords: Amino Acid Oxidoreductases; Bacterial Infections and Mycoses; Biotechnology; Business; Dehydrogenase; Drugs and Therapies; Enzymes and Coenzymes; Glutamate Dehydrogenase; Glutamates; Glutamic Acid; Health and Medicine; Qualitic Biotechnology LLC EN Amino Acid Oxidoreductases Bacterial Infections and Mycoses Biotechnology Business Dehydrogenase Drugs and Therapies Enzymes and Coenzymes Glutamate Dehydrogenase Glutamates Glutamic Acid Health and Medicine Qualitic Biotechnology LLC 3580 3580 1 03/27/23 20230328 NES 230328 2023 MAR 31 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Qualitic Biotechnology LLC (Atlanta, Georgia, United States) has been issued patent number 11597961, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. Amino Acid Oxidoreductases, Bacterial Infections and Mycoses, Biotechnology, Business, Dehydrogenase, Drugs and Therapies, Enzymes and Coenzymes, Glutamates, Glutamic Acid, Health and Medicine, Qualitic Biotechnology LLC, Glutamate Dehydrogenase. [Extracted from the article]

"Because of the coupling effect, this media is commonly referred to as an ultrasound couplant, ultrasound gel, scanning gel, ultrasound transmission media or acoustic transmission media. The system of claim 18, further comprising a first packaging layer and a second packaging layer held within a packaging pouch that holds the first layer, the at least one second layer, and the third layer therein." Obstetric sonography is the use of medical ultrasonography in pregnancy, in which sound waves are used to create real-time visual images of the developing embryo or fetus in its mother's uterus. The ultrasound coupling gel displaces air and fills contours between the piezoelectric eye, or transducer, of an ultrasound instrument (such as a probe or scanhead), which converts energy between electrical and acoustic, and the body into which the sound is being directed. [Extracted from the article]

Edison Liu, MD, President and CEO Emeritus of the Jackson Laboratory, has joined Verseon's scientific advisory board. Dr. Liu is an internationally recognized expert in cancer biology, functional genomics, and translational medicine. He has held various leadership positions in the field, including serving as the founding executive director of the Genome Institute of Singapore and president of the Human Genome Organization. Dr. Liu's expertise will be valuable in advancing Verseon's technology for drug development, particularly in the field of cancer research. [Extracted from the article]

Baxter International Inc. has been issued a patent for a reconstitution system that allows for the administration of medications via intravenous (IV) bags. The system includes a reconstitution device with a vent conduit, which improves the reconstitution process, especially for multi-chamber bags. The device enables the mixing of IV fluid with a drug located in a vial, and air pressure from the external environment pushes the mixed drug from the vial to the IV bag. This system aims to improve the administration of medications and provide a more efficient and convenient method for healthcare professionals. [Extracted from the article]

Crystal Bio, a division of Crystal Pharmatech, has announced the appointment of Dr. Shiaw-Lin (Billy) Wu as its new co-founder and Chief Scientific Officer. Dr. Wu has over 30 years of experience in analytical and bioanalytical analysis of biologics for CMC development. He has worked at Genentech and ThermoFisher, and co-founded BioAnalytix. Crystal Pharmatech, established in 2010, is a leading CRO/CDMO specializing in solid-state research, formulation development, and GMP manufacturing. Their First-Time-Right polymorph and formulation technology sets them apart from other CRO/CDMOs. [Extracted from the article]

SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co. Ltd., has adopted Veeva Vault Validation Management to streamline and accelerate their validation process. By using this validation solution, the company can execute digital validation while centralizing data and improving visibility. This shift to a digital approach allows for greater efficiency, data integrity, and audit readiness, reducing compliance risks. SK Life Science, Inc. is committed to developing next-generation treatments for central nervous system disorders and cancer care. [Extracted from the article]

A patent has been issued for redundant traces in flexible circuits used in an energy delivery device. The device emits high frequency electromagnetic energy to treat skin tissue by heating it and causing collagen to contract and tighten. The flexible circuit in the device includes an electronic component and multiple traces that provide parallel current paths, enhancing reliability and preventing trace failure. This invention aims to improve the performance and longevity of energy delivery devices used in treating various skin conditions. [Extracted from the article]

A patent application has been submitted by Kemeny Healthcare Inc. for wearable light stimulation systems and methods. The application describes how light stimulation therapy, also known as photobiomodulation (PBM), can enhance testosterone levels in the body when applied to the testes. The patent application includes details of a light stimulation system that consists of a flexible substrate carrying light emitters, a controller, a thin film reflective layer, and temperature sensors. The system is designed to provide a selected irradiance in a duty cycle to enhance testosterone levels. [Extracted from the article]

A patent has been issued to Cerner Innovation Inc. for a technology that aims to maintain the context of clinically relevant information when displayed on various user interfaces, including mobile devices. The technology provides an overview of relevant clinical data in a flowsheet or timeline format, allowing for correlation of clinical events, assessment of patient conditions, and determination of treatments. It also allows for the display of medication information grouped by classification. The patent describes methods and systems for presenting this information in a way that is readable and efficient for clinicians. [Extracted from the article]

A patent application by inventor Amir Genosar has been made available online for a packaging system with a molded component. The system is designed to store injectable medications in a sterile and aseptic manner until they are ready for use. The primary package includes a compartment with a flexible wall that encloses a storage volume for the medication, and a rigid section that connects to a secondary package. The flexible wall can collapse to deplete the storage volume and expel the medication through a dispensing port. The packaging system can be made of various materials and can include features such as vents and seals to maintain sterility and pressure equilibration. [Extracted from the article]

A patent has been issued for an implantable electric multi-pole connection structure by Neuroloop GmbH. The invention aims to address the challenges of connecting electric implants to feed and discharge structures, such as the need for space and moisture resistance. The new design utilizes a flexible, film-like, electrically non-conductive strip-shaped surface element that connects the implant to the feed and discharge structure. This structure can accommodate a large number of electrical feed lines without requiring additional installation space and reduces patient stress and irritation. The patent provides detailed descriptions and claims for the implantable electrical multi-pole connection structure. [Extracted from the article]

Using a knowledge graph which is populated with all known molecules, input molecules are analyzed according to various similarity indexes which relate the input molecules to target proteins or other biological entities. The system of claim 1, wherein the report comprises molecule hypotheses surrounding the potential uses of the one or more received molecules. The method of claim 11, wherein the report comprises molecule hypotheses surrounding the potential uses of the one or more received molecules. [Extracted from the article]

The promising result will further support Insilico's UAE team to integrate the hybrid Quantum GAN model into Chemistry42, Insilico's proprietary small molecule generation engine to obtain more efficient and accurate results in AI-driven drug discovery and development process. Keywords: Business; Chemistry; Insilico Medicine; Insilico Medicine Inc.; Technology EN Business Chemistry Insilico Medicine Insilico Medicine Inc. Technology 694 694 1 05/29/23 20230602 NES 230602 2023 MAY 29 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Insilico Medicine, a clinical stage generative artificial intelligence (AI)-driven drug discovery company, announced that it groundbreakingly combines two rapidly developing technologies, quantum computing and generative AI to explore the lead candidate discovery in the drug development process and successfully demonstrated the potential advantages of quantum generative adversarial networks in generative chemistry. [Extracted from the article]

GranBio Intellectual Property Holdings LLC has been issued a patent for compatibilizers for polymer-nanocellulose composites. The patent describes the use of nanocellulose, which is derived from biomass, in a wide range of applications such as polymer reinforcement, biodegradable food packaging, pharmaceuticals, and textiles. The invention also includes a maleated polymer as a compatibilizer to improve the stability and mechanical properties of the composite. The patent provides detailed information on the composition and process for producing these polymer-nanocellulose composites. [Extracted from the article]

A patent has been issued to Cerner Innovation Inc. for a system and method of maintaining context and displaying clinically relevant information across various user interfaces, including mobile devices. The technology aims to address the challenges faced by early electronic health record systems, such as difficulties in consolidating patient information and displaying it in a readable and efficient manner. The system includes features such as timelines, diagnostic parameters, duration indicators, and medication classifications to assist clinicians in reviewing and assessing patient conditions. The patent provides a detailed description of the system's functionalities and includes multiple claims. [Extracted from the article]

When the electrodes deliver radio-frequency (RF) energy to the tissue, the large surface area of the electrodes can contribute to unwanted tissue sticking. "Surgical instruments may also include additional components such as electrodes, sensing devices, processing circuits, motors, and wiring and/or wiring traces, some of which can be located within various portions of a surgical instrument. For example, a sensing device and/or a processing circuit can be located within an end effector of the surgical instrument, within a shaft assembly of the surgical instrument and/or within a handle assembly of the surgical instrument. [Extracted from the article]

In another set of embodiments, the device includes a fluid sample device comprising a fluid transporter for receiving fluid from the subject, and a storage chamber for receiving fluid withdrawn from the subject via the fluid transporter. In some embodiments, the device comprises a fluid transporter and a storage chamber for receiving blood withdrawn from the subject, and in some cases, the storage chamber may be in fluid communication with the fluid transporter. In some cases, the storage chamber is in fluid communication with the fluid transporter, and in certain embodiments, the interface may define a fluid pathway for transporting fluid into and/or out of the fluid storage chamber. According to yet another set of embodiments, the device includes a fluid transporter for receiving fluid from the subject, and a storage chamber for receiving fluid withdrawn from the subject via the fluid transporter. [Extracted from the article]

It may comprise one or more of: polyisoprene, polybutadiene, styrene-butadiene copolymers, ethylene-propylene copolymers, ethylene-propylene-diene copolymers, chlorosulphonated polyethylene, ethylene-vinyl acetate copolymer, styrene-isoprene copolymers, fluoroelastomers, butyl rubber, isoprene rubber, butadiene rubber, halogenated butyl rubber, ethylene propylene terpolymer, silicone rubber, and combinations thereof." Acyclic Hydrocarbons, Alkenes, Business, Ethylenes, Pharmaceutical Companies, Pharmaceutical Services Companies, West Pharmaceutical Services Inc Keywords: Acyclic Hydrocarbons; Alkenes; Business; Ethylenes; Pharmaceutical Companies; Pharmaceutical Services Companies; West Pharmaceutical Services Inc EN Acyclic Hydrocarbons Alkenes Business Ethylenes Pharmaceutical Companies Pharmaceutical Services Companies West Pharmaceutical Services Inc 8103 8103 1 10/24/23 20231027 NES 231027 2023 OCT 27 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- West Pharmaceutical Services Inc. (Exton, Pennsylvania, United States) has been issued patent number 11771623, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]

The terms dispenser, dispensing device, delivery device and delivering device are used interchangeably herein. The pre-filled cartridge assembly of claim 1, wherein the delivery device with which the distal end of the administration device is configured to engage comprises a syringe. Yet most of injectable medication are stored in aseptic packages and are transferred to a dispensing device (i.e. drug delivery device) shortly before use. The pre-filled cartridge assembly of claim 1, wherein when the administration device is configured such that when the administration device is engaged with the delivery device: the administration device establishes fluid communication between the package and the delivery device, thereby allowing withdrawal of beneficial agent from the package to the delivery device; and thereafter, when removed from the coupler, allows administration of the beneficial agent from the delivery device to a subject through the administration device. [Extracted from the article]

The transport packaging (20) according to claim 9, further comprising a plurality of petri-dishes (P) accommodated in the slots (12) of the rack (1). While this cassette arrangement provides for a safe transport of the petri-dish held in the interior space of the cassette housing, it is not useful for automated handling as it is specifically directed to a manual operation by a finger in order to at least release the petri-dish from the housing. [Extracted from the article]

"There are various types of peritoneal dialysis therapies, including continuous ambulatory peritoneal dialysis ("CAPD"), automated peritoneal dialysis ("APD"), tidal flow dialysis and continuous flow peritoneal dialysis ("CFPD"). The patient then switches fluid communication so that the patient catheter communicates with a bag of fresh dialysis fluid to infuse the fresh dialysis fluid through the catheter and into the patient. APD machines pump fresh dialysis fluid from a dialysis fluid source, through the catheter and into the patient's peritoneal cavity. "Another type of kidney failure therapy is peritoneal dialysis ("PD"), which infuses a dialysis solution, also called dialysis fluid, into a patient's peritoneal cavity via a catheter. [Extracted from the article]

Autolomous, a developer of manufacturing management systems for cell and gene therapies, has partnered with BioCentriq, a clinical-phase Cell Therapy CDMO, to digitize and accelerate process development and manufacturing activities. Autolomous' autoloMATE platform is a cloud-native software designed to improve efficiency and data integrity in the cell and gene therapy sector. BioCentriq will use the autoloMATE platform to streamline its operations and enhance the client experience, ultimately speeding up the delivery of cutting-edge cell therapies to patients. This collaboration aims to revolutionize healthcare innovation and make life-saving therapies more accessible to those in need. [Extracted from the article]

The US Patent and Trademark Office has published a patent application titled "Pharmaceutical Manufacturing Process Control, Support and Analysis" by inventor Matthias Friebe. The patent application focuses on quality control procedures and support for pharmaceutical manufacturing processes, specifically addressing the challenges of maintaining quality and uniformity in decentralized manufacturing. The invention proposes a computer apparatus that uses augmented reality (AR) headsets to assist operators in laboratory procedures and generate a batch record (BR) by populating a master batch record (MBR). The apparatus includes features such as extracting data from analyses, interpreting graph data, and transmitting overlay images to the AR headset for operator review and input. It also includes modules for quality control checks, batch release decisions, and communication between the operator and a qualified person. [Extracted from the article]

BrainStorm Cell Therapeutics Inc. has announced the publication of Phase 3 biomarker data in Muscle and Nerve. The study suggests that their investigational cell therapy, debamestrocel or NurOwn, may impact key biomarkers in amyotrophic lateral sclerosis (ALS) that are predictive of disease progression. The study analyzed forty-five biomarkers and identified three that are predictive of clinical outcomes in debamestrocel-treated participants. Treatment with debamestrocel led to significant changes in 64% of the analyzed biomarkers, indicating potential benefits for patients with ALS. [Extracted from the article]

C.R. Bard Inc. has been granted a patent for a catheterization package that aims to improve the accuracy of diagnosing catheter-associated urinary tract infections (CAUTI) and reduce the risk of contamination. The package includes a urinary catheter, a urine-drainage bag, and a sampling-port access device, all held in a catheterization tray. The patent provides detailed descriptions of the components and step-by-step instructions for the catheterization procedure. NewsRx LLC is a reliable source for fact-based news on various topics, including C.R. Bard Inc., catheterization, and healthcare technology companies, making it a valuable resource for library patrons conducting research in a culturally sensitive and respectful manner. [Extracted from the article]

The US Patent and Trademark Office has published a patent application for a laser irradiation device used for oral treatment. The device is designed to target areas vulnerable to oral mucositis in the oral cavity and improve the effectiveness of low-level laser therapy. The device includes a customized mouthpiece, a base frame, an LED strip, and a liquid light-transparent resin material. The patent application provides detailed descriptions and diagrams of the device and its manufacturing process. [Extracted from the article]

Bluesight Inc. has been issued a patent for the management of pharmacy kits using multiple acceptance criteria. The patent describes a method and system for managing pharmacy kits in hospitals, which often contain groups of medical items for specific procedures or conditions. The invention aims to address challenges such as medication shortages by allowing for the use of substitute items and providing electronic information processing systems to track and manage inventory. The patent includes various claims and can be accessed for further information. [Extracted from the article]

Softwave Tissue Regeneration Technologies LLC has been granted a patent for their acoustic shock wave therapeutic methods, which can be used to prevent or treat opioid addiction. The patent explains that acoustic shock waves or pressure pulses can be used to regulate and stimulate glandular hormonal secretions. This technology can also be used to reduce a patient's pain caused by a medical condition or procedure, thereby reducing the need for addictive pain medications. The treatment involves administering acoustic shock waves or pressure pulses to reflexology zones or areas near the source of pain. This method has been scientifically validated to recruit and activate endogenous stem cells, providing long-lasting relief for chronic pain. By targeting reflexology zones on the hands, feet, or ears, as well as the area near the source of pain or medical condition, the shock waves can stimulate these zones, modulating the patient's response and reducing anxiety and pain. Additionally, this treatment can reduce inflammation and initiate or activate stem cells. It can be repeated over several weeks and can serve as a substitute for addictive medications with non-addictive alternatives. [Extracted from the article]

A patent has been issued for surgical mesh implants made from poly(butylene succinate) and copolymers. These implants are strong, biocompatible, and degrade into non-toxic substances. They can be used for hernia repair, breast reconstruction, and orthopedic repairs. The patent also discusses the use of 3D printing to create porous structures for the implants. The invention aims to address issues such as maintaining the size and shape of the implants and preventing tissue damage. [Extracted from the article]

Business, Consumer Goods Companies, Drugs and Therapies, Health and Medicine, Healthcare Technology Companies, Johnson & Johnson Consumer Inc., Therapeutics, Therapy Keywords: Business; Consumer Goods Companies; Drugs and Therapies; Health and Medicine; Healthcare Technology Companies; Johnson & Johnson Consumer Inc.; Therapeutics; Therapy EN Business Consumer Goods Companies Drugs and Therapies Health and Medicine Healthcare Technology Companies Johnson & Johnson Consumer Inc. Therapeutics Therapy 3618 3618 1 08/28/23 20230829 NES 230829 2023 SEP 1 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- A patent by the inventors Alary, Marc (Skillman, NJ, US), Liu, Jan-Joo (Skillman, NJ, US), Patel, Bharat (Skillman, NJ, US), filed on June 27, 2018, was published online on August 8, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. It's also called medical make-up, corrective camouflage make-up or camouflage make-up. [Extracted from the article]

"Some embodiments provide a drilling fluid additive comprising hydrophobic lignin-coated cellulose nanofibers and/or hydrophobic lignin-coated cellulose nanocrystals, wherein the additive further comprises lignosulfonates. "Some embodiments provide a drilling fluid additive comprising hydrophobic lignin-coated cellulose nanofibers and/or hydrophobic lignin-coated cellulose nanocrystals. [Extracted from the article]

The wearable drug delivery device of claim 1, wherein the shell component of the reservoir is positioned against an interior of the bottom surface of the wearable drug delivery device. The wearable drug delivery device of claim 8, wherein the shell component of the reservoir is positioned against an interior of the bottom surface of the wearable drug delivery device. The wearable drug delivery device of claim 8, wherein the reservoir further comprises: one or more drainage channels formed in the shell component that directly contact the liquid drug when the liquid drug is stored in the reservoir. [Extracted from the article]

Biopharmaceuticals, Business, Drugs and Therapies, Health and Medicine, Medical Technology Companies, Sartorius Stedim Fmt SAS Keywords: Biopharmaceuticals; Business; Drugs and Therapies; Health and Medicine; Medical Technology Companies; Sartorius Stedim Fmt SAS EN Biopharmaceuticals Business Drugs and Therapies Health and Medicine Medical Technology Companies Sartorius Stedim Fmt SAS 4138 4138 1 06/12/23 20230612 NES 230612 2023 JUN 16 (NewsRx) -- By a News Reporter-Staff News Editor at Pharma Business Week -- Sartorius Stedim Fmt SAS (Aubagne, France) has been issued patent number 11654084, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]

The user connects the drug vial to the adapter and then opens a frangible valve to allow the diluent to flow into the vial and dissolve the drug, and then causes the mixture to flow back into the diluent bag. The layers may each include one or more polymers, such as polypropylene ("PP"), propylene-ethylene copolymer ("EPR") and/or a styrene-olefin-styrene block copolymer elastomer (commonly referred to as styrene ethylene butylene styrene ("SEBS") or styrene ethylene propylene styrene ("SEPS"), and which may include other elastomers. Ordinarily, this requires the pharmacist to withdraw a syringeful of diluent from a separate IV solution container, inject the diluent into the vial to dissolve the drug, withdraw the dissolved drug from the vial via syringe and reinject the drug into the IV container to prepare a drug solution ready for administration. [Extracted from the article]